News Nicox glaucoma drug works, but not as well as hoped Nicox has had both good and bad news from a much-anticipated phase 3 trial of its glaucoma therapy candidate NCX 470.
News Oral Wegovy bolsters Novo in Q3 Novo has raised its financial guidance for 2026 on the back of rising sales of its oral weight-loss therapy Wegovy.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
